GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoCellular Therapeutics Ltd (FRA:KOL1) » Definitions » Issuance of Stock

ImmunoCellular Therapeutics (FRA:KOL1) Issuance of Stock : €0.00 Mil (TTM As of Jun. 2018)


View and export this data going back to . Start your Free Trial

What is ImmunoCellular Therapeutics Issuance of Stock?

ImmunoCellular Therapeutics's Issuance of Stock for the three months ended in Jun. 2018 was €0.00 Mil.

ImmunoCellular Therapeutics's Issuance of Stock for the trailing twelve months (TTM) ended in Jun. 2018 was €0.00 Mil.


ImmunoCellular Therapeutics Issuance of Stock Historical Data

The historical data trend for ImmunoCellular Therapeutics's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunoCellular Therapeutics Issuance of Stock Chart

ImmunoCellular Therapeutics Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Issuance of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.58 3.65 13.40 6.67 -

ImmunoCellular Therapeutics Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Issuance of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ImmunoCellular Therapeutics Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ImmunoCellular Therapeutics Issuance of Stock Related Terms

Thank you for viewing the detailed overview of ImmunoCellular Therapeutics's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


ImmunoCellular Therapeutics (FRA:KOL1) Business Description

Traded in Other Exchanges
N/A
Address
136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.

ImmunoCellular Therapeutics (FRA:KOL1) Headlines

No Headlines